The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Katsuhiro Hayashi - One of the best experts on this subject based on the ideXlab platform.
-
salvage method for unplanned excision of Soft Tissue Sarcoma long term results of second look surgery following radio hyperthermo chemotherapy
Anticancer Research, 2015Co-Authors: Katsuhiro Hayashi, Satoshi Yamada, Hiroyuki Inatani, Hideki Okamoto, Akihiko Takeuchi, Hideji Nishida, Norio Yamamoto, Hiroyuki TsuchiyaAbstract:We have established a "second-look operation" protocol that consists of whole biopsy of surgical scar Tissue following radio-hyperthermo-chemotherapy (RHC) after unplanned excision of Soft Tissue Sarcoma. Out of 30 patients who underwent RHC for Soft Tissue Sarcoma at our Institution, 6 were enrolled into this study to undergo a second-look operation for unplanned excision. Radiotherapy was given to a total dose of 32 Gy. Hyperthermia was conducted once a week, for a total of five sessions. Chemotherapy was performed at weekly intervals. Surgery was performed to excise the scar Tissue that was enhanced on preoperative MRI. In all six cases, no residual tumors were identified in resected scar Tissue; thus, no additional wide excision was performed. The average follow-up period was 10.9 years. There were no local recurrences, and all patients were alive at their final follow-up. Long-term follow-up confirmed that RHC can replace additional wide excision for unplanned excision of Soft Tissue Sarcoma.
-
Inhibition of spontaneous and experimental lung metastasis of Soft-Tissue Sarcoma by tumor-targeting Salmonella typhimurium A1-R
Oncotarget, 2014Co-Authors: Shinji Miwa, Yong Zhang, Kyung-eun Baek, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Yukihiko Hiroshima, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro HayashiAbstract:Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor. Therefore, novel systemic therapy is needed to improve the survival of Soft-Tissue Sarcoma. In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium, termed A1-R, was evaluated. Mouse models of primary Soft Tissue Sarcoma and spontaneous lung metastasis were obtained by orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the treated group (P = 0.024). A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium A1-R significantly reduced lung metastases and improved overall survival (P = 0.004). S. typhimurium A1-R bacterial therapy has future potential for treating advanced Soft Tissue Sarcoma and improving prognosis of patients with lung metastasis.
-
inhibition of spontaneous and experimental lung metastasis of Soft Tissue Sarcoma by tumor targeting salmonella typhimurium a1 r
Oncotarget, 2014Co-Authors: Shinji Miwa, Yong Zhang, Kyung-eun Baek, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Yukihiko Hiroshima, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro HayashiAbstract:// Shinji Miwa 1, 2, 3 , Yong Zhang 1, 2 , Kyung-Eun Baek 1 , Fuminari Uehara 1, 2 , Shuya Yano 1, 2 , Mako Yamamoto 1, 2 , Yukihiko Hiroshima 1, 2 , Yasunori Matsumoto 1, 2 , Hiroaki Kimura 3 , Katsuhiro Hayashi 3 , Norio Yamamoto 3 , Michael Bouvet 2 , Hiroyuki Tsuchiya 3 , Robert M. Hoffman 1, 2 , Ming Zhao 1 1 AntiCancer, Inc., San Diego, California, USA 2 Department of Surgery, University of California, San Diego, San Diego, California, USA 3 Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan Correspondence to: Robert M. Hoffman or Ming Zhao, e-mail: all@anticancer.com Keywords: HT-1080; orthotopic model; nude mice; lung metastasis; bacterial therapy Received: August 22, 2014 Accepted: October 01, 2014 Published: December 30, 2014 ABSTRACT Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor. Therefore, novel systemic therapy is needed to improve the survival of Soft-Tissue Sarcoma. In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium , termed A1-R, was evaluated. Mouse models of primary Soft Tissue Sarcoma and spontaneous lung metastasis were obtained by orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the treated group ( P = 0.024). A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium A1-R significantly reduced lung metastases and improved overall survival ( P = 0.004). S. typhimurium A1-R bacterial therapy has future potential for treating advanced Soft Tissue Sarcoma and improving prognosis of patients with lung metastasis.
Shinji Miwa - One of the best experts on this subject based on the ideXlab platform.
-
inhibition of Soft Tissue Sarcoma lung metastasis by tumor targeting salmonella typhimurium a1 r
Journal of Clinical Oncology, 2015Co-Authors: Shinji Miwa, Yong Zhang, Hiroyuki Tsuchiya, Michael Bouvet, Robert M Hoffman, Ming ZhaoAbstract:e13515 Background: Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor, therefore, more effective therapeutics are needed. Methods: In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium, termed A1-R, was evaluated on mouse models of primary Soft Tissue Sarcoma where spontaneous lung metastasis occurred after orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. Results: The number of spontaneous lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the S. typhimurium A1-R treated group (P = 0.024). S. typhimurium A1-R also s...
-
Inhibition of spontaneous and experimental lung metastasis of Soft-Tissue Sarcoma by tumor-targeting Salmonella typhimurium A1-R
Oncotarget, 2014Co-Authors: Shinji Miwa, Yong Zhang, Kyung-eun Baek, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Yukihiko Hiroshima, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro HayashiAbstract:Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor. Therefore, novel systemic therapy is needed to improve the survival of Soft-Tissue Sarcoma. In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium, termed A1-R, was evaluated. Mouse models of primary Soft Tissue Sarcoma and spontaneous lung metastasis were obtained by orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the treated group (P = 0.024). A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium A1-R significantly reduced lung metastases and improved overall survival (P = 0.004). S. typhimurium A1-R bacterial therapy has future potential for treating advanced Soft Tissue Sarcoma and improving prognosis of patients with lung metastasis.
-
inhibition of spontaneous and experimental lung metastasis of Soft Tissue Sarcoma by tumor targeting salmonella typhimurium a1 r
Oncotarget, 2014Co-Authors: Shinji Miwa, Yong Zhang, Kyung-eun Baek, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Yukihiko Hiroshima, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro HayashiAbstract:// Shinji Miwa 1, 2, 3 , Yong Zhang 1, 2 , Kyung-Eun Baek 1 , Fuminari Uehara 1, 2 , Shuya Yano 1, 2 , Mako Yamamoto 1, 2 , Yukihiko Hiroshima 1, 2 , Yasunori Matsumoto 1, 2 , Hiroaki Kimura 3 , Katsuhiro Hayashi 3 , Norio Yamamoto 3 , Michael Bouvet 2 , Hiroyuki Tsuchiya 3 , Robert M. Hoffman 1, 2 , Ming Zhao 1 1 AntiCancer, Inc., San Diego, California, USA 2 Department of Surgery, University of California, San Diego, San Diego, California, USA 3 Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan Correspondence to: Robert M. Hoffman or Ming Zhao, e-mail: all@anticancer.com Keywords: HT-1080; orthotopic model; nude mice; lung metastasis; bacterial therapy Received: August 22, 2014 Accepted: October 01, 2014 Published: December 30, 2014 ABSTRACT Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor. Therefore, novel systemic therapy is needed to improve the survival of Soft-Tissue Sarcoma. In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium , termed A1-R, was evaluated. Mouse models of primary Soft Tissue Sarcoma and spontaneous lung metastasis were obtained by orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the treated group ( P = 0.024). A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium A1-R significantly reduced lung metastases and improved overall survival ( P = 0.004). S. typhimurium A1-R bacterial therapy has future potential for treating advanced Soft Tissue Sarcoma and improving prognosis of patients with lung metastasis.
Murray F Brennan - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary metastasectomy with therapeutic intent for Soft Tissue Sarcoma
The Journal of Thoracic and Cardiovascular Surgery, 2017Co-Authors: Neel P Chudgar, Murray F Brennan, Rodrigo Ramella Munhoz, Peter R Bucciarelli, Kay See Tan, Sandra P Dangelo, Manjit S Bains, Matthew J Bott, James Huang, Bernard J ParkAbstract:Abstract Objective Soft-Tissue Sarcoma is a heterogeneous disease that frequently includes the development of pulmonary metastases. The purpose of this study is to determine factors associated with improved survival among patients with Soft-Tissue Sarcoma to help guide selection for pulmonary metastasectomy. Methods We reviewed a prospectively maintained database and identified 803 patients who underwent pulmonary metastasectomy for metastatic Soft-Tissue Sarcoma between September 1991 and June 2014; of these, 539 patients undergoing 760 therapeutic-intent pulmonary metastasectomies were included. Clinicopathologic variables and characteristics of treatment were examined. The outcomes of interest were overall survival and disease-free survival. Survival was estimated with the Kaplan-Meier method and compared between variables with the log-rank test. Factors associated with hazard of death and recurrence were identified via the use of univariable and multivariable Cox proportional hazards models. Results Median overall survival was 33.2 months (95% confidence interval, 29.9-37.1), and median disease-free survival was 6.8 months (95% confidence interval, 6.0-8.0). In multivariable analyses, leiomyoSarcoma histologic subtype ( P = .007), primary tumor size ≤10 cm ( P = .006), increasing time from primary tumor resection to development of metastases ( P P = .001), and minimally invasive resection ( P = .023) were associated with lower hazard of death. Disease-free interval ≥1 year ( P = .002), and 1 pulmonary metastasis ( P Conclusions In a large single-institution study, primary tumor histologic subtype and size, numbers of pulmonary metastases, disease-free interval, and selection for minimally invasive resection are associated with increased survival in patients undergoing pulmonary metastasectomy for Soft-Tissue Sarcoma.
-
toward better Soft Tissue Sarcoma staging building on american joint committee on cancer staging systems versions 6 and 7
Annals of Surgical Oncology, 2013Co-Authors: Robert G Maki, Cristina R Antonescu, Samuel Singer, Nicole Moraco, Meera Hameed, Alisa Pinkhasik, Murray F BrennanAbstract:Background Based on review of patient data in case conferences over time, we hypothesized that clinically relevant data are omitted in routine Soft Tissue Sarcoma staging.
-
cost effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic Soft Tissue Sarcoma a combined analysis from the university of texas m d anderson and memorial sloan kettering cancer centers
The Journal of Thoracic and Cardiovascular Surgery, 2004Co-Authors: Geoffrey A Porter, Scott B Cantor, Garrett L Walsh, Valerie W Rusch, Dennis Leung, Alma Yvette Dejesus, Raphael E Pollock, Murray F Brennan, Peter W T PistersAbstract:Abstract Background We sought to determine the cost-effectiveness of different treatment strategies for patients with pulmonary metastases from Soft Tissue Sarcoma. Methods We constructed a decision tree to model the outcomes of 4 treatment strategies for patients with pulmonary metastases from Soft Tissue Sarcoma: pulmonary resection, systemic chemotherapy, pulmonary resection and systemic chemotherapy, and no treatment. Data from 1124 patients with pulmonary metastases from Soft Tissue Sarcoma were used to estimate disease-specific survival for pulmonary resection and no treatment. Outcomes of systemic chemotherapy and pulmonary resection and of systemic chemotherapy were estimated by assuming a 12-month improvement in disease-specific survival with chemotherapy; this was done on the basis of the widely held but unproven assumption that chemotherapy provides a survival benefit in patients with metastatic Soft Tissue Sarcoma. Direct costs were examined for a series of patients who underwent protocol-based pulmonary resection or doxorubicin/ifosfamide-based chemotherapy. Results The mean cost of pulmonary resection was $20,339 per patient; the mean cost of 6 cycles of chemotherapy was $99,033. Compared with no treatment and assuming a 12-month survival advantage with chemotherapy, the incremental cost-effectiveness ratio was $14,357 per life-year gained for pulmonary resection, $104,210 per life-year gained for systemic chemotherapy, and $51,159 per life-year gained for pulmonary resection and systemic chemotherapy. Compared with pulmonary resection, the incremental cost-effectiveness ratio of pulmonary resection and systemic chemotherapy was $108,036 per life-year gained. Sensitivity analyses showed that certain patient and tumor features, as well as the assumed benefit of chemotherapy, affected cost-effectiveness. Conclusions For patients with pulmonary metastases from Soft Tissue Sarcoma who were surgical candidates, pulmonary resection was the most cost-effective treatment strategy evaluated. Even with favorable assumptions regarding its clinical benefit, systemic chemotherapy alone, compared with no treatment, was not a cost-effective treatment strategy for these patients.
-
classification and subtype prediction of adult Soft Tissue Sarcoma by functional genomics
American Journal of Pathology, 2003Co-Authors: Neil H Segal, Paul Pavlidis, Cristina R Antonescu, Robert G Maki, William Stafford Noble, Diann Desantis, James M Woodruff, Jonathan Lewis, Murray F BrennanAbstract:Adult Soft Tissue Sarcomas are a heterogeneous group of tumors, including well-described subtypes by histological and genotypic criteria, and pleomorphic tumors typically characterized by non-recurrent genetic aberrations and karyotypic heterogeneity. The latter pose a diagnostic challenge, even to experienced pathologists. We proposed that gene expression profiling in Soft Tissue Sarcoma would identify a genomic-based classification scheme that is useful in diagnosis. RNA samples from 51 pathologically confirmed cases, representing nine different histological subtypes of adult Soft Tissue Sarcoma, were examined using the Affymetrix U95A GeneChip. Statistical tests were performed on experimental groups identified by cluster analysis, to find discriminating genes that could subsequently be applied in a support vector machine algorithm. Synovial Sarcomas, round-cell/myxoid lipoSarcomas, clear-cell Sarcomas and gastrointestinal stromal tumors displayed remarkably distinct and homogenous gene expression profiles. Pleomorphic tumors were heterogeneous. Notably, a subset of malignant fibrous histiocytomas, a controversialhistological subtype, was identified as a distinct genomic group. The support vector machine algorithm supported a genomic basis for diagnosis, with both high sensitivity and specificity. In conclusion, we showed gene expression profiling to be useful in classification and diagnosis, providing insights into pathogenesis and pointing to potential new therapeutic targets of Soft Tissue Sarcoma.
-
primary adult Soft Tissue Sarcoma time dependent influence of prognostic variables
Journal of Clinical Oncology, 2002Co-Authors: Alexander Stojadinovic, Peter J Allen, Denis H Y Leung, David P Jaques, Jonathan J Lewis, Murray F BrennanAbstract:PURPOSE: To define prognostic factors for postrelapse survival and their time-dependent influence for adult Soft Tissue Sarcoma (STS). PATIENTS AND METHODS: We analyzed 2,123 patients with completely resected localized primary STS treated from 1982 to 1999. Variables studied included tumor site, size, depth, grade, and resection margin but not treatment other than resection. Landmark time frames were used to assess the influence of disease-free interval (DFI) on disease-specific survival (DSS). DSS was estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed using log-rank test and the Cox proportional hazards regression model. Time-dependent stepwise regression analysis evaluated the time-dependent influence of each variable. RESULTS: Two thirds of recurrences developed within 2 years of initial resection. Tumor size (P < .001), grade (P < .001), and microscopic resection margin (P < .001) independently predicted DSS for all STS. Size and grade independently predicted e...
Yong Zhang - One of the best experts on this subject based on the ideXlab platform.
-
inhibition of Soft Tissue Sarcoma lung metastasis by tumor targeting salmonella typhimurium a1 r
Journal of Clinical Oncology, 2015Co-Authors: Shinji Miwa, Yong Zhang, Hiroyuki Tsuchiya, Michael Bouvet, Robert M Hoffman, Ming ZhaoAbstract:e13515 Background: Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor, therefore, more effective therapeutics are needed. Methods: In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium, termed A1-R, was evaluated on mouse models of primary Soft Tissue Sarcoma where spontaneous lung metastasis occurred after orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. Results: The number of spontaneous lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the S. typhimurium A1-R treated group (P = 0.024). S. typhimurium A1-R also s...
-
Inhibition of spontaneous and experimental lung metastasis of Soft-Tissue Sarcoma by tumor-targeting Salmonella typhimurium A1-R
Oncotarget, 2014Co-Authors: Shinji Miwa, Yong Zhang, Kyung-eun Baek, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Yukihiko Hiroshima, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro HayashiAbstract:Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor. Therefore, novel systemic therapy is needed to improve the survival of Soft-Tissue Sarcoma. In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium, termed A1-R, was evaluated. Mouse models of primary Soft Tissue Sarcoma and spontaneous lung metastasis were obtained by orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the treated group (P = 0.024). A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium A1-R significantly reduced lung metastases and improved overall survival (P = 0.004). S. typhimurium A1-R bacterial therapy has future potential for treating advanced Soft Tissue Sarcoma and improving prognosis of patients with lung metastasis.
-
inhibition of spontaneous and experimental lung metastasis of Soft Tissue Sarcoma by tumor targeting salmonella typhimurium a1 r
Oncotarget, 2014Co-Authors: Shinji Miwa, Yong Zhang, Kyung-eun Baek, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Yukihiko Hiroshima, Yasunori Matsumoto, Hiroaki Kimura, Katsuhiro HayashiAbstract:// Shinji Miwa 1, 2, 3 , Yong Zhang 1, 2 , Kyung-Eun Baek 1 , Fuminari Uehara 1, 2 , Shuya Yano 1, 2 , Mako Yamamoto 1, 2 , Yukihiko Hiroshima 1, 2 , Yasunori Matsumoto 1, 2 , Hiroaki Kimura 3 , Katsuhiro Hayashi 3 , Norio Yamamoto 3 , Michael Bouvet 2 , Hiroyuki Tsuchiya 3 , Robert M. Hoffman 1, 2 , Ming Zhao 1 1 AntiCancer, Inc., San Diego, California, USA 2 Department of Surgery, University of California, San Diego, San Diego, California, USA 3 Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan Correspondence to: Robert M. Hoffman or Ming Zhao, e-mail: all@anticancer.com Keywords: HT-1080; orthotopic model; nude mice; lung metastasis; bacterial therapy Received: August 22, 2014 Accepted: October 01, 2014 Published: December 30, 2014 ABSTRACT Prognosis of patients with lung metastases of Soft-Tissue Sarcoma is still poor. Therefore, novel systemic therapy is needed to improve the survival of Soft-Tissue Sarcoma. In the present study, tumor-targeting therapy with a genetically-modified auxotrophic strain of Salmonella typhimurium , termed A1-R, was evaluated. Mouse models of primary Soft Tissue Sarcoma and spontaneous lung metastasis were obtained by orthotopic intra-muscular injection of HT1080-RFP human fibroSarcoma cells. S. typhimurium A1-R was administered from day 14, once a week for two weeks. On day 28, lung samples were excised and observed with a fluorescence imaging system. The number of lung metastasis was 8.8 ± 3.4 in the untreated group and 0.8 ± 0.8 in the treated group ( P = 0.024). A mouse model of experimental lung metastasis was obtained by tail vein injection of HT1080-RFP cells. The mice were treated with S. typhimurium A1-R (i.v.) on day 7, once a week for three weeks. S. typhimurium A1-R significantly reduced lung metastases and improved overall survival ( P = 0.004). S. typhimurium A1-R bacterial therapy has future potential for treating advanced Soft Tissue Sarcoma and improving prognosis of patients with lung metastasis.
Elizabeth H Baldini - One of the best experts on this subject based on the ideXlab platform.
-
surveillance imaging patterns and outcomes following radiation therapy and radical resection for localized extremity and trunk Soft Tissue Sarcoma
Annals of Surgical Oncology, 2017Co-Authors: Sagar A Patel, Trevor J Royce, Constance M Barysauskas, Katherine Thornton, Chandrajit P Raut, Elizabeth H BaldiniAbstract:Background Optimal surveillance imaging (SI) regimens following radiation therapy (RT) and radical resection for localized Soft Tissue Sarcoma (STS) are unknown and practice patterns vary.
-
predictors for major wound complications following preoperative radiotherapy and surgery for Soft Tissue Sarcoma of the extremities and trunk importance of tumor proximity to skin surface
Annals of Surgical Oncology, 2013Co-Authors: Elizabeth H Baldini, Michelle R Lapidus, Qian Wang, Judith Manola, Dennis P Orgill, Bohdan Pomahac, Karen J MarcusAbstract:Purpose Preoperative and postoperative RT for the treatment of high-grade Soft-Tissue Sarcoma result in similar local control and overall survival rates, but morbidities differ. Postoperative RT is associated with a higher rate of long-term fibrosis, edema, and joint stiffness. Preoperative RT is associated with higher rates of wound complications. It is important to identify predictors for major wound complications (MWC) and to develop strategies to minimize this outcome. We reviewed our experience to determine predictors for MWC following preoperative radiotherapy (RT) and surgery for Soft-Tissue Sarcoma.
